Corient Private Wealth
IMNM icon

Corient Private Wealth’s Immunome IMNM Stock Holding History

Corient Private Wealth’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$951K Sell
43,477
-42,929
-50% -$955K ﹤0.01% 1692
2025
Q4 		$1.86M Buy
86,406
+43,203
+100% +$758K ﹤0.01% 1562
2025
Q3 		$506K Buy
+43,203
New +$430K ﹤0.01% 1782
2025
Q1 		– Sell
-12,085
Closed -$128K – 2358
2024
Q4 		$128K Sell
12,085
-12,149
-50% -$147K ﹤0.01% 2197
2024
Q3 		$354K Buy
+24,234
New +$344K ﹤0.01% 1934

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Corient Private Wealth's IMNM Position: Q1 2026 in Review

Corient Private Wealth reduced its Immunome (IMNM) stake by 50% in Q1 2026, selling an estimated $955K and leaving 43,477 shares worth $951K. The position accounts for ﹤0.01% of the portfolio, ranked #1692.

Corient Private Wealth first reported a position in IMNM in Q3 2024 and has held it in 5 quarters since. The position peaked at $1.86M in Q4 2025. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Corient Private Wealth held 43,477 shares of Immunome worth $951K as of Q1 2026.
  • Corient Private Wealth sold 42,929 Immunome shares in Q1 2026, an estimated $955K.
  • Immunome made up ﹤0.01% of Corient Private Wealth's portfolio in Q1 2026, its #1692 holding.
  • Corient Private Wealth first reported a position in Immunome in Q3 2024 and has held it in 5 quarters since.
  • Corient Private Wealth's Immunome position peaked at $1.86M in Q4 2025.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.